160 related articles for article (PubMed ID: 34514571)
1. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions.
Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN
Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571
[TBL] [Abstract][Full Text] [Related]
2. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience.
Rekhi B; Ghate S; Shah A; Ramadwar M; Gulia A
Ann Diagn Pathol; 2020 Feb; 44():151440. PubMed ID: 31862519
[TBL] [Abstract][Full Text] [Related]
4. p63 expression in giant cell-containing lesions of bone and soft tissue.
de la Roza G
Arch Pathol Lab Med; 2011 Jun; 135(6):776-9. PubMed ID: 21631272
[TBL] [Abstract][Full Text] [Related]
5. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics.
Guimarães LM; Baumhoer D; Andrei V; Friedel D; Koelsche C; Gomez RS; von Deimling A; Gomes CC
J Pathol Clin Res; 2023 Nov; 9(6):464-474. PubMed ID: 37555357
[TBL] [Abstract][Full Text] [Related]
7. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.
Maues De Paula A; Vasiljevic A; Giorgi R; Gomez-Brouchet A; Aubert S; Leroy X; Duval H; de Pinieux G; Bouvier C
Virchows Arch; 2014 Oct; 465(4):487-94. PubMed ID: 25100342
[TBL] [Abstract][Full Text] [Related]
8. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
9. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
10. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
11. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
12. [Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value].
Wang X; Wu N; Zhang RS; Wei X; Ji RH; Ma HH; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):116-121. PubMed ID: 32074722
[No Abstract] [Full Text] [Related]
13. Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours.
Cleven AHG; Schreuder WH; Groen E; de Lange J; Briaire-de Bruijn IH; Bovée JVMG
Virchows Arch; 2022 Oct; 481(4):671-675. PubMed ID: 35612673
[TBL] [Abstract][Full Text] [Related]
14. p63 as a prognostic marker for giant cell tumor of bone.
Yanagisawa M; Kakizaki H; Okada K; Torigoe T; Kusumi T
Ups J Med Sci; 2013 Mar; 118(1):23-8. PubMed ID: 23033898
[TBL] [Abstract][Full Text] [Related]
15. Giant cell tumor of bone express p63.
Dickson BC; Li SQ; Wunder JS; Ferguson PC; Eslami B; Werier JA; Turcotte RE; Kandel RA
Mod Pathol; 2008 Apr; 21(4):369-75. PubMed ID: 18311114
[TBL] [Abstract][Full Text] [Related]
16. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques].
Macagno N; Caselles K; Aubert S; Audard V; Gomez-Brouchet A; Galant C; Guinebretière JM; Karanian M; Larousserie F; Marie B; de Pinieux G; Bouvier C
Ann Pathol; 2018 Apr; 38(2):92-102. PubMed ID: 29580573
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
[TBL] [Abstract][Full Text] [Related]
18. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience.
Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A
Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB
Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965
[TBL] [Abstract][Full Text] [Related]
20. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
